Richard I. Fisher, MD, has been named Executive Vice President and Physician-in-Chief of Fox Chase Cancer Center, where he will oversee seven clinical departments. He will also be one of two Deputy Directors of the Fox Chase Cancer Center Support Grant. Fisher has also been named Senior Associate Dean at Temple University School of Medicine, and will report to the Dean of the School of Medicine. He assumes the roles March 1.
“Clearly, Richard Fisher's proven talents as a leader in cancer medicine and science will enable us to maximize the opportunities brought forth by the recent addition of Fox Chase Cancer Center to the Temple University Health System,” said Larry R. Kaiser, MD, FACS, Dean of the Temple University School of Medicine and President and CEO of Temple University Health System.
Fisher most recently served as Vice President for Strategic and Program Development at the University of Rochester Medical Center, where he was also the Samuel E. Durand Professor of Medicine. And, for the past 11 years, he has served as Director of the James P. Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry and Director of Cancer Services for the Strong Health System in Rochester.
Rogerio C. Lilenbaum, MD, has been appointed Chief Medical Officer of Smilow Cancer Hospital at Yale-New Haven. He will continue to practice medical oncology and care for patients through the Thoracic Oncology Program. He most recently served as Chairman of the Cancer Institute at the Cleveland Clinic in Florida.
““Dr. Lilenbaum's life has been about caring for patients with lung cancer. He has done pioneering work in defining the best way to treat lung cancer—particularly in older patients,” Thomas J. Lynch, Jr., MD, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven, said in a news release.
Lilenbaum has also served as Director of Cancer Research and Director of the Thoracic Oncology Program at Mount Sinai Medical Center in Florida and the principal investigator of the Mount Sinai Community Clinical Oncology Program.
Ross Brownson, PhD, Professor of Medicine and Social Work at Washington University and a research member of the Siteman Cancer Center, has been named President-Elect of the American College of Epidemiology. He is also co-director of the Prevention Research Center in St. Louis, led by Washington University and Saint Louis University and funded by the U.S. Centers for Disease Control and Prevention.
Axel Ullrich, PhD, Director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, was awarded the Lennox K. Black International Prize for Excellence in Biomedical Research by Thomas Jefferson University. His research about the overexpression of the HER2 gene in breast cancer from the mid-1980s led to the development of trastuzumab.
Laurie H. Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and Provost for Medical Affairs of Cornell University, has received the Dr. Luis Federico Leloir Prize of International Cooperation in Science, Technology, and Innovation from Argentina's Ministry of Science, Technology, and Productive Innovation. She was recognized for her collaborations on investigating immune responses in cancer with Argentinian physician scientists, including Gabriel Rabinovich, PhD, Head of the Laboratory of Immunopathology at the Institute of Biology and Experimental Medicine of the Argentinean National Research Council and Professor of Immunology at the Faculty of Exact and Natural Sciences at the University of Buenos Aires, and Eduardo Arzt, PhD, Member of the Research Scientific Career of the National Research Council of Argentina, Professor at the University of Buenos Aires, and Director of the BioMedicine Institute of Buenos Aires—CONICET—Partner Institute Max Planck Society.
“It is exciting and deeply humbling to accept this high accolade from Argentina's Ministry of Science, Technology, and Productive Innovation,” Glimcher said in a news release. “Science and medicine shouldn't have any barriers or borders hindering its advancement to heal patients. The most significant and pivotal biomedical research discoveries are often the result of meaningful collaborations, and it is among my deepest honors to be able to contribute to the successes of fellow investigators in Argentina and science around the globe.”
Debra Auguste, PhD, Associate Professor of Biomedical Engineering in the Grove School of Engineering at City College of New York, has been given a National Institutes of Health Director's New Innovator Award to investigate personalized therapies using complementary engineered liposomes in four metastatic breast cancer populations: black women, white women, women over 40, and women under 40. The grant awards $1.5 million over five years.
“We need to understand how multiple proteins work together to engineer adhesion,” she said in a news release. “If we can understand that, we can hopefully go from a non-adhesive vehicle to one that is adhesive in order to trigger a favorable response. The key is adhesion of the drug delivery vehicle to tumor cells.”
The Breast Cancer Research Foundation will award the first grant from the newly established Evelyn H. Lauder Founder's Fund of more than $8 million to support a large multi-institutional, international research project. The project will focus on using new genetic sequencing technologies and sophisticated procedures for tissue sample collection and analysis to find ways to lower breast cancer mortality.
Erin K. O'Shea, PhD, a Howard Hughes Medical Institute Investigator at Harvard University, has been elected Vice President and Chief Scientific Officer at Howard Hughes Medical Institute. She is a member of both the National Academy of Sciences and the American Academy of Arts and Sciences. Her research focuses on gene regulation, signal transduction, and systems biology.
O'Shea has served as Director of the Harvard Faculty of Arts and Sciences Center for Systems Biology for the last seven years, and is the Paul C. Magelsdorf Professor of Molecular and Cellular Biology and Chemistry and Chemical Biology at Harvard. She has also served at the University of California, San Francisco, and has been an HHMI investigator since 2000. She begins the new position this month, and transition to her full-time role in July.
Richard Zellars, MD, Associate Professor of Radiation Oncology, has been appointed Assistant Director for Clinical Trial Accrual at Johns Hopkins Sidney Kimmel Cancer Center. And, Dina George Lansey, MSN, RN, OCN, has been recruited to partner with Zellars as a Research Associate and Clinical Recruitment Specialist.
Zellars will be responsible for initiatives to increase accrual to therapeutic clinical trials with a special emphasis on minority accrual. And, he will continue his academic and clinical positions as a breast and gynecologic cancer radiation oncologist. Lansey has extensive nursing experience as both a primary nurse in the outpatient setting as well as a clinical trials research nurse, including having served as the liaison between the Cancer Center's research nursing staff and the outpatient clinic nurses regarding clinical trial protocols to improve communication, continuity of care and data quality.
In more news from Johns Hopkins:
* Judith E. Karp, MD, Professor of Oncology and Medicine and Director of the Leukemia Program at the Kimmel Cancer Center, has received the Merrill J. Egorin Outstanding Mentor Award for her dedication and effort to the next generation of cancer researchers. She was selected for the award by the students at the 2012 AACR/ASCO Methods in Clinical Research workshop, held in Vail, Colo.; and
* Cornelia Trimble, MD, Director of the Center for Cervical Dysplasia at the Kimmel Cancer Center, has received the Center of Talented Youth's inaugural Distinguished Alumni Award, which recognizes highly accomplished alumni for “making a difference in the world.”
ASH Annual Meeting Awards
Samuel Silver, MD, PhD, Assistant Dean for Research and Professor of Internal Medicine and Hematology-Oncology at the University of Michigan Medical School, has been presented an Exemplary Service Award by the American Society of Hematology for his leadership in advancing the practice and physician reimbursement priorities of the Society. He has served as ASH Councillor and as Chair of both the Committee on Practice and the Subcommittee on Reimbursement, and has held appointments on several other special task forces and committees.
“Dr. Silver's efforts have been instrumental in the Society's ability to influence physician reimbursement,” ASH 2012 President Armand Keating, MD, of Princess Margaret Cancer Centre, University Health Network in Toronto, said in a news release.
Also recognized at the Annual Meeting were Beverly S. Mitchell, MD, and Rainer F. Storb, MD, with Mentor Awards to recognize their sustained, outstanding commitment to the training and career development of junior hematologists.
“The Society thanks Drs. Mitchell and Storb for their service that has not only been critical to the personal career successes of their mentees, but has also been essential to advancing research breakthroughs and the development of therapies that have helped improve the care of patients with blood disorders,” Keating said.
Mitchell, who received the 2012 Mentor Award for Clinical Investigation, is Director of the Stanford Cancer Institute and the George E. Becker Professor of Medicine at Stanford University. Mitchell served as ASH President in 2001 and played a key role in developing the ASH Clinical Research Training Institute.
Storb, who received the 2012 Mentor Award for Basic Science, is Head and Member of the Transplantation Biology Program at Fred Hutchinson Cancer Research Center and Professor of Medicine at the University of Washington in Seattle. He participated in the founding of the Hutchinson Center in 1975, and has mentored more than 150 trainees while there. He has also previously been honored with the ASH 1997 Henry M. Stratton Medal and the ASH 2005 E. Donnall Thomas Lecture and Prize.
Share Your News!
Send information and photos for this column to OT@LWWNY.com© 2013 Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...